Based in Durham, North Carolina, Grid Therapeutics was founded in 2014 by Edward F. Patz, Jr. MD and his team of scientists from Duke University Medical Center. Their innovative approach involves identifying specific tumor immunoglobulin G (IgG) antibodies from early-stage cancer patients, which directly kill tumor cells without harming normal tissues and enhance the immune response against tumors. The company's lead asset, "GT103," is currently enrolling patients for a Phase 1 clinical trial in refractory NSCLC patients, with plans to expand to advanced-stage solid tumor patients in early 2019.